» Articles » PMID: 28261219

Naturally Acquired Binding-Inhibitory Antibodies to Duffy Binding Protein in Pregnant Women Are Associated with Higher Birth Weight in a Multicenter Study

Abstract

A vaccine to eliminate malaria would need a multi-stage and multi-species composition to achieve robust protection, but the lack of knowledge about antigen targets and mechanisms of protection precludes the development of fully efficacious malaria vaccines, especially for (Pv). Pregnant women constitute a risk population who would greatly benefit from a vaccine preventing the adverse events of infection during gestation. We hypothesized that functional immune responses against putative targets of naturally acquired immunity to malaria and vaccine candidates will be associated with protection against malaria infection and/or poor outcomes during pregnancy. We measured (i) IgG responses to a large panel of Pv and (Pf) antigens, (ii) the capacity of anti-Pv ligand Duffy binding protein (PvDBP) antibodies to inhibit binding to Duffy antigen, and (iii) cellular immune responses to two Pv antigens, in a subset of 1,056 pregnant women from Brazil, Colombia, Guatemala, India, and Papua New Guinea (PNG). There were significant intraspecies and interspecies correlations for most antibody responses (e.g., PfMSP1 versus PfAMA1, Spearman's rho = 0.81). Women from PNG and Colombia had the highest levels of IgG overall. Submicroscopic infections seemed sufficient to boost antibody responses in Guatemala but not antigen-specific cellular responses in PNG. Brazil had the highest percentage of Duffy binding inhibition (-values versus Colombia: 0.040; Guatemala: 0.047; India: 0.003, and PNG: 0.153) despite having low anti-PvDBP IgG levels. Almost all antibodies had a positive association with present infection, and coinfection with the other species increased this association. Anti-PvDBP, anti-PfMSP1, and anti-PfAMA1 IgG levels at recruitment were positively associated with infection at delivery (-values: 0.010, 0.003, and 0.023, respectively), suggesting that they are markers of malaria exposure. Peripheral blood mononuclear cells from Pv-infected women presented fewer CD8IFN-γ T cells and secreted more G-CSF and IL-4 independently of the stimulus used . Functional anti-PvDBP levels at recruitment had a positive association with birth weight (difference per doubling antibody levels: 45 g, -value: 0.046). Thus, naturally acquired binding-inhibitory antibodies to PvDBP might confer protection against poor outcomes of Pv malaria in pregnancy.

Citing Articles

Acquisition of antibodies to Plasmodium falciparum and Plasmodium vivax antigens in pregnant women living in a low malaria transmission area of Brazil.

Kassa M, Hasang W, Barateiro A, Damelang T, Brewster J, Dombrowski J Malar J. 2022; 21(1):360.

PMID: 36457056 PMC: 9714246. DOI: 10.1186/s12936-022-04402-4.


Strong off-target antibody reactivity to malarial antigens induced by RTS,S/AS01E vaccination is associated with protection.

Macia D, Campo J, Moncunill G, Jairoce C, Nhabomba A, Mpina M JCI Insight. 2022; 7(10).

PMID: 35446785 PMC: 9220828. DOI: 10.1172/jci.insight.158030.


High Antibodies to VAR2CSA in Response to Malaria Infection Are Associated With Improved Birthweight in a Longitudinal Study of Pregnant Women.

McLean A, Opi D, Stanisic D, Cutts J, Feng G, Ura A Front Immunol. 2021; 12:644563.

PMID: 34220804 PMC: 8242957. DOI: 10.3389/fimmu.2021.644563.


Adverse pregnancy outcomes are associated with Plasmodium vivax malaria in a prospective cohort of women from the Brazilian Amazon.

Dombrowski J, Barateiro A, Peixoto E, Barros A, de Souza R, Clark T PLoS Negl Trop Dis. 2021; 15(4):e0009390.

PMID: 33914739 PMC: 8112668. DOI: 10.1371/journal.pntd.0009390.


Cytokine signatures of Plasmodium vivax infection during pregnancy and delivery outcomes.

Dobano C, Bardaji A, Arevalo-Herrera M, Martinez-Espinosa F, Botto-Menezes C, Padilla N PLoS Negl Trop Dis. 2020; 14(5):e0008155.

PMID: 32365058 PMC: 7224570. DOI: 10.1371/journal.pntd.0008155.


References
1.
Arevalo-Herrera M, Chitnis C, Herrera S . Current status of Plasmodium vivax vaccine. Hum Vaccin. 2009; 6(1):124-32. DOI: 10.4161/hv.6.1.9931. View

2.
Woodberry T, Minigo G, Piera K, Hanley J, de Silva H, Salwati E . Antibodies to Plasmodium falciparum and Plasmodium vivax merozoite surface protein 5 in Indonesia: species-specific and cross-reactive responses. J Infect Dis. 2008; 198(1):134-42. PMC: 6485435. DOI: 10.1086/588711. View

3.
Herrera S, Bonelo A, Perlaza B, Valencia A, Cifuentes C, Hurtado S . Use of long synthetic peptides to study the antigenicity and immunogenicity of the Plasmodium vivax circumsporozoite protein. Int J Parasitol. 2004; 34(13-14):1535-46. DOI: 10.1016/j.ijpara.2004.10.009. View

4.
Higgins M . Overproduction, purification and crystallization of a chondroitin sulfate A-binding DBL domain from a Plasmodium falciparum var2csa-encoded PfEMP1 protein. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2008; 64(Pt 3):221-3. PMC: 2374165. DOI: 10.1107/S1744309108004211. View

5.
Fowkes F, McGready R, Cross N, Hommel M, Simpson J, Elliott S . New insights into acquisition, boosting, and longevity of immunity to malaria in pregnant women. J Infect Dis. 2012; 206(10):1612-21. PMC: 3475637. DOI: 10.1093/infdis/jis566. View